Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pulmonary Disease, Chronic Obstructive | 45 | 2024 | 199 | 10.560 |
Why?
|
Patient Readmission | 13 | 2024 | 162 | 3.500 |
Why?
|
Patient Discharge | 11 | 2023 | 153 | 3.260 |
Why?
|
Exercise Therapy | 13 | 2019 | 74 | 2.980 |
Why?
|
Transitional Care | 6 | 2024 | 20 | 2.930 |
Why?
|
Aged | 82 | 2024 | 6417 | 2.830 |
Why?
|
Self Care | 14 | 2017 | 175 | 2.750 |
Why?
|
Humans | 125 | 2024 | 18430 | 2.650 |
Why?
|
Quality of Life | 25 | 2022 | 529 | 2.590 |
Why?
|
Exercise | 12 | 2020 | 495 | 2.580 |
Why?
|
Male | 86 | 2024 | 10440 | 2.470 |
Why?
|
Internet | 13 | 2016 | 243 | 2.400 |
Why?
|
Dyspnea | 16 | 2018 | 48 | 2.300 |
Why?
|
Dementia | 5 | 2024 | 105 | 2.290 |
Why?
|
Walking | 13 | 2019 | 87 | 2.280 |
Why?
|
Female | 88 | 2024 | 13136 | 2.230 |
Why?
|
Heart Failure | 5 | 2024 | 398 | 2.130 |
Why?
|
Delivery of Health Care, Integrated | 5 | 2021 | 567 | 1.960 |
Why?
|
Hospitalization | 15 | 2023 | 847 | 1.870 |
Why?
|
Middle Aged | 58 | 2024 | 8284 | 1.790 |
Why?
|
Home Care Services | 3 | 2021 | 23 | 1.630 |
Why?
|
Aged, 80 and over | 27 | 2020 | 2003 | 1.570 |
Why?
|
Vietnam | 22 | 2022 | 34 | 1.500 |
Why?
|
Telemedicine | 5 | 2024 | 184 | 1.380 |
Why?
|
Health Education | 7 | 2019 | 115 | 1.330 |
Why?
|
Anxiety | 9 | 2021 | 156 | 1.310 |
Why?
|
Mentoring | 2 | 2019 | 28 | 1.280 |
Why?
|
Medicare | 9 | 2021 | 214 | 1.270 |
Why?
|
Retrospective Studies | 17 | 2024 | 2550 | 1.250 |
Why?
|
Social Support | 8 | 2019 | 214 | 1.240 |
Why?
|
Depression | 11 | 2021 | 518 | 1.190 |
Why?
|
Medicare Part C | 2 | 2023 | 22 | 1.180 |
Why?
|
Disease Progression | 6 | 2020 | 271 | 1.150 |
Why?
|
Pandemics | 4 | 2024 | 292 | 1.140 |
Why?
|
Motor Activity | 4 | 2015 | 215 | 1.140 |
Why?
|
Hospitals | 6 | 2022 | 80 | 1.050 |
Why?
|
Patient Education as Topic | 7 | 2015 | 214 | 1.040 |
Why?
|
United States | 23 | 2024 | 4164 | 1.040 |
Why?
|
Adult | 29 | 2024 | 7910 | 1.040 |
Why?
|
Health Care Costs | 4 | 2019 | 251 | 0.970 |
Why?
|
Aftercare | 3 | 2022 | 48 | 0.960 |
Why?
|
Alzheimer Disease | 2 | 2022 | 43 | 0.950 |
Why?
|
Emergency Service, Hospital | 2 | 2019 | 382 | 0.940 |
Why?
|
Fitness Centers | 3 | 2008 | 10 | 0.930 |
Why?
|
Health Knowledge, Attitudes, Practice | 5 | 2019 | 392 | 0.930 |
Why?
|
Caregivers | 6 | 2022 | 126 | 0.930 |
Why?
|
Palliative Care | 3 | 2021 | 58 | 0.920 |
Why?
|
Time Factors | 10 | 2018 | 1136 | 0.900 |
Why?
|
Outpatients | 3 | 2021 | 111 | 0.900 |
Why?
|
Cross-Sectional Studies | 19 | 2022 | 1360 | 0.880 |
Why?
|
Surveys and Questionnaires | 16 | 2021 | 1389 | 0.820 |
Why?
|
Self Report | 3 | 2020 | 256 | 0.800 |
Why?
|
Skilled Nursing Facilities | 2 | 2021 | 8 | 0.790 |
Why?
|
Risk Assessment | 6 | 2019 | 1143 | 0.770 |
Why?
|
Influenza Vaccines | 4 | 2024 | 290 | 0.750 |
Why?
|
Unemployment | 1 | 2020 | 11 | 0.750 |
Why?
|
Influenza, Human | 4 | 2024 | 282 | 0.750 |
Why?
|
Prospective Studies | 14 | 2024 | 1314 | 0.750 |
Why?
|
Treatment Outcome | 14 | 2024 | 1296 | 0.740 |
Why?
|
Patient-Centered Care | 4 | 2021 | 228 | 0.740 |
Why?
|
Monitoring, Ambulatory | 3 | 2011 | 18 | 0.730 |
Why?
|
Patient Transfer | 4 | 2021 | 24 | 0.730 |
Why?
|
Cost-Benefit Analysis | 3 | 2019 | 270 | 0.730 |
Why?
|
Employment | 1 | 2020 | 48 | 0.720 |
Why?
|
Terminal Care | 2 | 2018 | 36 | 0.700 |
Why?
|
Hospice and Palliative Care Nursing | 1 | 2019 | 6 | 0.690 |
Why?
|
House Calls | 1 | 2019 | 13 | 0.690 |
Why?
|
Accelerometry | 4 | 2019 | 37 | 0.670 |
Why?
|
Pragmatic Clinical Trials as Topic | 2 | 2024 | 56 | 0.670 |
Why?
|
Severity of Illness Index | 12 | 2021 | 476 | 0.660 |
Why?
|
Community Participation | 1 | 2019 | 33 | 0.640 |
Why?
|
Follow-Up Studies | 7 | 2021 | 1269 | 0.630 |
Why?
|
California | 7 | 2024 | 2365 | 0.620 |
Why?
|
Suicide, Assisted | 1 | 2018 | 3 | 0.620 |
Why?
|
Terminally Ill | 1 | 2018 | 9 | 0.620 |
Why?
|
Policy Making | 1 | 2018 | 18 | 0.620 |
Why?
|
Cell Phone | 2 | 2009 | 12 | 0.610 |
Why?
|
Longitudinal Studies | 12 | 2022 | 724 | 0.600 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2019 | 127 | 0.580 |
Why?
|
Biomarkers | 2 | 2024 | 308 | 0.580 |
Why?
|
Community Health Services | 2 | 2017 | 86 | 0.570 |
Why?
|
Managed Care Programs | 3 | 2008 | 347 | 0.570 |
Why?
|
Papillomavirus Infections | 1 | 2019 | 136 | 0.570 |
Why?
|
Health Policy | 1 | 2018 | 136 | 0.560 |
Why?
|
Drug Prescriptions | 1 | 2018 | 157 | 0.560 |
Why?
|
Insurance Coverage | 1 | 2018 | 136 | 0.560 |
Why?
|
Adolescent | 15 | 2024 | 3798 | 0.560 |
Why?
|
Pilot Projects | 9 | 2018 | 237 | 0.560 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 51 | 0.550 |
Why?
|
Practice Guidelines as Topic | 3 | 2017 | 333 | 0.550 |
Why?
|
Wounds and Injuries | 1 | 2016 | 51 | 0.550 |
Why?
|
Smartphone | 3 | 2021 | 11 | 0.550 |
Why?
|
Decision Making | 1 | 2018 | 204 | 0.540 |
Why?
|
Activities of Daily Living | 6 | 2009 | 96 | 0.540 |
Why?
|
Inpatients | 1 | 2016 | 80 | 0.530 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2022 | 342 | 0.530 |
Why?
|
Risk Factors | 10 | 2023 | 3449 | 0.520 |
Why?
|
Health Behavior | 4 | 2012 | 374 | 0.520 |
Why?
|
Physical Fitness | 4 | 2016 | 76 | 0.510 |
Why?
|
Self Efficacy | 6 | 2015 | 71 | 0.510 |
Why?
|
Rural Population | 3 | 2019 | 52 | 0.500 |
Why?
|
Unsafe Sex | 1 | 2015 | 19 | 0.490 |
Why?
|
Cohort Studies | 7 | 2023 | 2672 | 0.490 |
Why?
|
Sexual and Gender Minorities | 1 | 2015 | 27 | 0.480 |
Why?
|
Child Abuse | 2 | 2018 | 43 | 0.470 |
Why?
|
Risk-Taking | 1 | 2015 | 109 | 0.470 |
Why?
|
Antibodies, Viral | 2 | 2024 | 65 | 0.460 |
Why?
|
Lung Neoplasms | 1 | 2017 | 259 | 0.450 |
Why?
|
Logistic Models | 6 | 2019 | 962 | 0.450 |
Why?
|
Case-Control Studies | 5 | 2018 | 1173 | 0.440 |
Why?
|
Mental Health | 3 | 2014 | 168 | 0.430 |
Why?
|
Disability Evaluation | 3 | 2014 | 47 | 0.420 |
Why?
|
Prevalence | 10 | 2021 | 911 | 0.420 |
Why?
|
Arrhythmias, Cardiac | 1 | 2012 | 32 | 0.410 |
Why?
|
Reproducibility of Results | 6 | 2021 | 399 | 0.410 |
Why?
|
Recreation | 1 | 2012 | 37 | 0.410 |
Why?
|
Patient Compliance | 2 | 2016 | 318 | 0.400 |
Why?
|
Gait | 1 | 2011 | 7 | 0.400 |
Why?
|
Postural Balance | 1 | 2011 | 11 | 0.400 |
Why?
|
Patient Selection | 3 | 2018 | 198 | 0.400 |
Why?
|
Video Games | 1 | 2011 | 9 | 0.400 |
Why?
|
Nursing Informatics | 2 | 2010 | 2 | 0.390 |
Why?
|
Young Adult | 9 | 2024 | 2518 | 0.380 |
Why?
|
Affect | 3 | 2012 | 26 | 0.380 |
Why?
|
Postmenopause | 1 | 2012 | 267 | 0.380 |
Why?
|
Ergometry | 1 | 2011 | 2 | 0.380 |
Why?
|
Feedback, Psychological | 2 | 2015 | 5 | 0.380 |
Why?
|
Faculty, Nursing | 1 | 2010 | 3 | 0.380 |
Why?
|
Inservice Training | 1 | 2010 | 15 | 0.380 |
Why?
|
Advance Care Planning | 1 | 2010 | 12 | 0.370 |
Why?
|
Nursing Staff, Hospital | 2 | 2021 | 12 | 0.360 |
Why?
|
Needs Assessment | 1 | 2010 | 69 | 0.360 |
Why?
|
Veterans | 4 | 2022 | 138 | 0.360 |
Why?
|
Patient Participation | 3 | 2011 | 144 | 0.360 |
Why?
|
Health Promotion | 3 | 2008 | 294 | 0.360 |
Why?
|
Frailty | 2 | 2020 | 9 | 0.350 |
Why?
|
Regression Analysis | 3 | 2020 | 319 | 0.350 |
Why?
|
Cognitive Dysfunction | 2 | 2024 | 47 | 0.350 |
Why?
|
Reinforcement (Psychology) | 1 | 2009 | 2 | 0.350 |
Why?
|
Stress, Psychological | 2 | 2021 | 147 | 0.340 |
Why?
|
Washington | 5 | 2019 | 388 | 0.340 |
Why?
|
Feasibility Studies | 5 | 2018 | 120 | 0.340 |
Why?
|
Sex Factors | 6 | 2016 | 661 | 0.330 |
Why?
|
Self Concept | 1 | 2009 | 42 | 0.330 |
Why?
|
Exercise Test | 6 | 2015 | 45 | 0.330 |
Why?
|
Insurance Benefits | 2 | 2008 | 15 | 0.320 |
Why?
|
Cost of Illness | 3 | 2014 | 100 | 0.320 |
Why?
|
Communication | 1 | 2010 | 202 | 0.320 |
Why?
|
Delivery of Health Care | 4 | 2016 | 444 | 0.320 |
Why?
|
Socioeconomic Factors | 5 | 2019 | 673 | 0.320 |
Why?
|
Patient Satisfaction | 4 | 2012 | 232 | 0.320 |
Why?
|
Forced Expiratory Volume | 5 | 2017 | 69 | 0.320 |
Why?
|
Incidence | 4 | 2021 | 1314 | 0.310 |
Why?
|
Health Services for the Aged | 1 | 2008 | 15 | 0.310 |
Why?
|
Child | 8 | 2024 | 2571 | 0.300 |
Why?
|
Self-Assessment | 1 | 2007 | 17 | 0.300 |
Why?
|
Nursing Methodology Research | 1 | 2007 | 8 | 0.290 |
Why?
|
Survival Rate | 3 | 2017 | 269 | 0.280 |
Why?
|
Peptides | 2 | 2018 | 12 | 0.280 |
Why?
|
Health Status | 4 | 2013 | 328 | 0.280 |
Why?
|
Anti-Bacterial Agents | 2 | 2020 | 142 | 0.280 |
Why?
|
Quality of Health Care | 2 | 2021 | 347 | 0.270 |
Why?
|
Body Mass Index | 2 | 2024 | 974 | 0.270 |
Why?
|
Diabetes Mellitus | 2 | 2008 | 530 | 0.270 |
Why?
|
International Classification of Diseases | 2 | 2021 | 87 | 0.270 |
Why?
|
Hand Strength | 3 | 2020 | 11 | 0.260 |
Why?
|
Cough | 2 | 2015 | 22 | 0.260 |
Why?
|
Mass Vaccination | 1 | 2005 | 22 | 0.250 |
Why?
|
Child, Preschool | 5 | 2024 | 1478 | 0.250 |
Why?
|
Hemagglutination Inhibition Tests | 1 | 2024 | 7 | 0.240 |
Why?
|
Chickenpox | 1 | 2005 | 38 | 0.240 |
Why?
|
Vaccination | 5 | 2024 | 674 | 0.240 |
Why?
|
Family Characteristics | 1 | 2024 | 54 | 0.240 |
Why?
|
Pain | 3 | 2024 | 84 | 0.240 |
Why?
|
Virus Shedding | 1 | 2024 | 1 | 0.240 |
Why?
|
Antigens, Viral | 1 | 2024 | 3 | 0.240 |
Why?
|
Cardiac Rehabilitation | 1 | 2004 | 3 | 0.240 |
Why?
|
Vaccines, Synthetic | 1 | 2024 | 43 | 0.240 |
Why?
|
Fatigue | 3 | 2024 | 35 | 0.240 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2024 | 56 | 0.240 |
Why?
|
Evaluation Studies as Topic | 1 | 2004 | 35 | 0.240 |
Why?
|
Vaccines, Inactivated | 1 | 2024 | 70 | 0.230 |
Why?
|
Interleukin-8 | 1 | 2024 | 4 | 0.230 |
Why?
|
Chickenpox Vaccine | 1 | 2005 | 101 | 0.230 |
Why?
|
Qualitative Research | 4 | 2018 | 272 | 0.230 |
Why?
|
Hyperkalemia | 1 | 2024 | 17 | 0.230 |
Why?
|
Quality Improvement | 2 | 2016 | 207 | 0.230 |
Why?
|
Multivariate Analysis | 3 | 2016 | 598 | 0.220 |
Why?
|
Frail Elderly | 2 | 2020 | 9 | 0.220 |
Why?
|
Family | 2 | 2021 | 120 | 0.220 |
Why?
|
Registries | 3 | 2018 | 490 | 0.210 |
Why?
|
Walk Test | 2 | 2019 | 5 | 0.210 |
Why?
|
Suicidal Ideation | 2 | 2014 | 100 | 0.210 |
Why?
|
Brain Concussion | 1 | 2022 | 1 | 0.200 |
Why?
|
Military Personnel | 1 | 2022 | 12 | 0.200 |
Why?
|
Electronic Health Records | 2 | 2020 | 747 | 0.200 |
Why?
|
Prognosis | 4 | 2019 | 624 | 0.200 |
Why?
|
Age Factors | 3 | 2016 | 965 | 0.200 |
Why?
|
Motivation | 3 | 2021 | 137 | 0.200 |
Why?
|
Outcome Assessment (Health Care) | 4 | 2015 | 254 | 0.200 |
Why?
|
Comorbidity | 4 | 2022 | 619 | 0.200 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2022 | 59 | 0.190 |
Why?
|
Fear | 1 | 2021 | 13 | 0.190 |
Why?
|
Work Engagement | 1 | 2021 | 1 | 0.190 |
Why?
|
Monitoring, Physiologic | 2 | 2015 | 41 | 0.190 |
Why?
|
Proportional Hazards Models | 2 | 2020 | 743 | 0.190 |
Why?
|
Health Personnel | 2 | 2019 | 126 | 0.180 |
Why?
|
Walking Speed | 1 | 2020 | 3 | 0.180 |
Why?
|
Yoga | 2 | 2012 | 26 | 0.180 |
Why?
|
HIV Infections | 2 | 2018 | 695 | 0.180 |
Why?
|
Sarcopenia | 1 | 2020 | 11 | 0.180 |
Why?
|
Telephone | 1 | 2021 | 179 | 0.180 |
Why?
|
Attitude of Health Personnel | 2 | 2019 | 226 | 0.180 |
Why?
|
Geriatric Assessment | 1 | 2020 | 40 | 0.180 |
Why?
|
Muscle, Skeletal | 1 | 2020 | 32 | 0.180 |
Why?
|
Accidental Falls | 1 | 2020 | 40 | 0.180 |
Why?
|
Inflammation | 2 | 2018 | 63 | 0.170 |
Why?
|
Primary Health Care | 2 | 2024 | 848 | 0.170 |
Why?
|
Telomere | 1 | 2019 | 19 | 0.170 |
Why?
|
Chronic Pain | 1 | 2021 | 128 | 0.170 |
Why?
|
Independent Living | 1 | 2019 | 21 | 0.170 |
Why?
|
Attitude to Death | 1 | 2019 | 5 | 0.170 |
Why?
|
Geriatric Nursing | 1 | 2019 | 3 | 0.170 |
Why?
|
Program Evaluation | 1 | 2020 | 244 | 0.170 |
Why?
|
Occupational Stress | 1 | 2019 | 3 | 0.170 |
Why?
|
Psychiatric Status Rating Scales | 2 | 2016 | 129 | 0.170 |
Why?
|
Therapy, Computer-Assisted | 1 | 2019 | 11 | 0.170 |
Why?
|
Receptors, Atrial Natriuretic Factor | 3 | 2005 | 3 | 0.170 |
Why?
|
Occupational Diseases | 1 | 2019 | 42 | 0.160 |
Why?
|
Spouses | 1 | 2019 | 10 | 0.160 |
Why?
|
Bronchodilator Agents | 2 | 2016 | 21 | 0.160 |
Why?
|
Oregon | 1 | 2019 | 222 | 0.160 |
Why?
|
State Medicine | 1 | 2018 | 6 | 0.160 |
Why?
|
Social Class | 1 | 2019 | 125 | 0.160 |
Why?
|
Reference Values | 3 | 2007 | 93 | 0.160 |
Why?
|
Papillomaviridae | 1 | 2019 | 53 | 0.160 |
Why?
|
Ambulatory Care | 1 | 2020 | 266 | 0.160 |
Why?
|
Spirometry | 2 | 2015 | 65 | 0.160 |
Why?
|
Singing | 1 | 2018 | 1 | 0.160 |
Why?
|
Personal Autonomy | 1 | 2018 | 4 | 0.160 |
Why?
|
Cyclohexylamines | 1 | 2018 | 1 | 0.160 |
Why?
|
Ornithine | 1 | 2018 | 1 | 0.160 |
Why?
|
Psychotherapy | 1 | 2018 | 59 | 0.150 |
Why?
|
Multiple Myeloma | 1 | 2017 | 11 | 0.150 |
Why?
|
Antibodies, Monoclonal | 1 | 2017 | 21 | 0.150 |
Why?
|
Hip Fractures | 1 | 2018 | 68 | 0.150 |
Why?
|
Actigraphy | 3 | 2015 | 17 | 0.150 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 50 | 0.140 |
Why?
|
Environment Design | 2 | 2020 | 68 | 0.140 |
Why?
|
Abbreviated Injury Scale | 1 | 2016 | 1 | 0.140 |
Why?
|
Interviews as Topic | 1 | 2018 | 327 | 0.140 |
Why?
|
Injury Severity Score | 1 | 2016 | 10 | 0.140 |
Why?
|
Patient Outcome Assessment | 1 | 2017 | 29 | 0.140 |
Why?
|
Trauma Centers | 1 | 2016 | 7 | 0.140 |
Why?
|
Psychology, Adolescent | 1 | 2016 | 15 | 0.140 |
Why?
|
Attitude to Health | 1 | 2018 | 177 | 0.140 |
Why?
|
Learning | 1 | 2016 | 10 | 0.140 |
Why?
|
Violence | 1 | 2016 | 30 | 0.140 |
Why?
|
Medical Overuse | 1 | 2016 | 13 | 0.140 |
Why?
|
Sinusitis | 1 | 2016 | 14 | 0.140 |
Why?
|
Metered Dose Inhalers | 1 | 2016 | 5 | 0.140 |
Why?
|
Crime Victims | 1 | 2016 | 25 | 0.140 |
Why?
|
Prescription Drug Overuse | 1 | 2016 | 3 | 0.140 |
Why?
|
Adrenergic beta-Agonists | 1 | 2016 | 33 | 0.140 |
Why?
|
Age Distribution | 2 | 2015 | 261 | 0.140 |
Why?
|
Lung | 1 | 2016 | 62 | 0.140 |
Why?
|
Students | 1 | 2016 | 54 | 0.130 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2018 | 180 | 0.130 |
Why?
|
Continuity of Patient Care | 1 | 2017 | 112 | 0.130 |
Why?
|
Length of Stay | 1 | 2016 | 183 | 0.130 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2015 | 19 | 0.130 |
Why?
|
Self-Management | 1 | 2016 | 30 | 0.130 |
Why?
|
Research Report | 1 | 2015 | 22 | 0.130 |
Why?
|
Public Sector | 1 | 2015 | 9 | 0.130 |
Why?
|
Habits | 1 | 2015 | 7 | 0.130 |
Why?
|
Somatoform Disorders | 1 | 2015 | 6 | 0.130 |
Why?
|
Tics | 1 | 2015 | 3 | 0.130 |
Why?
|
Capacity Building | 1 | 2015 | 11 | 0.130 |
Why?
|
Diazomethane | 1 | 2015 | 1 | 0.130 |
Why?
|
Methionine | 1 | 2015 | 6 | 0.130 |
Why?
|
Child Abuse, Sexual | 2 | 2018 | 14 | 0.120 |
Why?
|
Health Services Research | 1 | 2016 | 264 | 0.120 |
Why?
|
Respiratory Function Tests | 2 | 2012 | 32 | 0.120 |
Why?
|
Wisconsin | 2 | 2024 | 10 | 0.120 |
Why?
|
Influenza A Virus, H3N2 Subtype | 2 | 2024 | 14 | 0.120 |
Why?
|
Recovery of Function | 2 | 2016 | 28 | 0.120 |
Why?
|
Smoking | 1 | 2017 | 494 | 0.120 |
Why?
|
Antibody Formation | 2 | 2024 | 7 | 0.120 |
Why?
|
Residence Characteristics | 2 | 2016 | 256 | 0.120 |
Why?
|
Research Design | 4 | 2018 | 402 | 0.110 |
Why?
|
Hospice Care | 1 | 2013 | 8 | 0.110 |
Why?
|
Exercise Tolerance | 2 | 2019 | 13 | 0.110 |
Why?
|
Physical Endurance | 1 | 2012 | 5 | 0.110 |
Why?
|
Pain Management | 1 | 2013 | 59 | 0.110 |
Why?
|
Vital Capacity | 1 | 2012 | 35 | 0.110 |
Why?
|
Infant | 3 | 2024 | 1245 | 0.110 |
Why?
|
Focus Groups | 3 | 2018 | 154 | 0.100 |
Why?
|
Guanylate Cyclase | 2 | 2002 | 2 | 0.100 |
Why?
|
Observational Studies as Topic | 2 | 2024 | 49 | 0.100 |
Why?
|
Chronic Disease | 3 | 2016 | 468 | 0.100 |
Why?
|
Sensitivity and Specificity | 2 | 2024 | 321 | 0.100 |
Why?
|
Patient Simulation | 1 | 2010 | 1 | 0.090 |
Why?
|
Telenursing | 1 | 2010 | 1 | 0.090 |
Why?
|
Manikins | 1 | 2010 | 2 | 0.090 |
Why?
|
Education, Distance | 1 | 2010 | 4 | 0.090 |
Why?
|
Research Personnel | 2 | 2021 | 30 | 0.090 |
Why?
|
Psychometrics | 2 | 2021 | 124 | 0.090 |
Why?
|
Factor Analysis, Statistical | 2 | 2018 | 36 | 0.090 |
Why?
|
Attitude to Computers | 1 | 2010 | 15 | 0.090 |
Why?
|
Probability | 2 | 2007 | 86 | 0.090 |
Why?
|
Life Style | 1 | 2012 | 342 | 0.090 |
Why?
|
Family Relations | 1 | 2009 | 18 | 0.090 |
Why?
|
User-Computer Interface | 1 | 2009 | 28 | 0.080 |
Why?
|
Mental Disorders | 1 | 2012 | 295 | 0.080 |
Why?
|
Cost Savings | 1 | 2007 | 25 | 0.080 |
Why?
|
Confidence Intervals | 1 | 2007 | 253 | 0.070 |
Why?
|
Models, Molecular | 2 | 2018 | 4 | 0.070 |
Why?
|
Consumer Behavior | 1 | 2007 | 30 | 0.070 |
Why?
|
Anti-Retroviral Agents | 2 | 2018 | 80 | 0.070 |
Why?
|
Down-Regulation | 2 | 2005 | 13 | 0.070 |
Why?
|
Disease Outbreaks | 1 | 2005 | 39 | 0.060 |
Why?
|
Amino Acid Motifs | 1 | 2005 | 1 | 0.060 |
Why?
|
Tyrosine | 1 | 2005 | 2 | 0.060 |
Why?
|
Measles | 1 | 2005 | 26 | 0.060 |
Why?
|
Tennessee | 1 | 2024 | 6 | 0.060 |
Why?
|
Access to Information | 1 | 2005 | 13 | 0.060 |
Why?
|
Evidence-Based Medicine | 2 | 2016 | 195 | 0.060 |
Why?
|
Seasons | 1 | 2005 | 105 | 0.060 |
Why?
|
Cell Culture Techniques | 1 | 2024 | 4 | 0.060 |
Why?
|
Linear Models | 2 | 2016 | 243 | 0.060 |
Why?
|
Influenza B virus | 1 | 2024 | 8 | 0.060 |
Why?
|
Health Maintenance Organizations | 1 | 2007 | 479 | 0.060 |
Why?
|
Computers, Handheld | 1 | 2024 | 11 | 0.060 |
Why?
|
Eggs | 1 | 2024 | 9 | 0.060 |
Why?
|
Immunogenicity, Vaccine | 1 | 2024 | 12 | 0.060 |
Why?
|
Stakeholder Participation | 1 | 2024 | 23 | 0.060 |
Why?
|
Antibodies, Neutralizing | 1 | 2024 | 6 | 0.060 |
Why?
|
Spironolactone | 1 | 2024 | 7 | 0.060 |
Why?
|
Immunization, Secondary | 1 | 2024 | 64 | 0.060 |
Why?
|
Mortality | 1 | 2005 | 123 | 0.060 |
Why?
|
Peer Group | 1 | 2004 | 48 | 0.060 |
Why?
|
Cause of Death | 1 | 2005 | 185 | 0.060 |
Why?
|
Health Surveys | 2 | 2016 | 269 | 0.060 |
Why?
|
C-Reactive Protein | 1 | 2024 | 58 | 0.060 |
Why?
|
Pulmonary Ventilation | 1 | 2003 | 2 | 0.050 |
Why?
|
Stroke Volume | 1 | 2024 | 98 | 0.050 |
Why?
|
Online Systems | 1 | 2003 | 8 | 0.050 |
Why?
|
Continental Population Groups | 2 | 2016 | 315 | 0.050 |
Why?
|
Cyclic GMP-Dependent Protein Kinases | 1 | 2002 | 1 | 0.050 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2002 | 2 | 0.050 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2002 | 2 | 0.050 |
Why?
|
Multicenter Studies as Topic | 1 | 2021 | 91 | 0.050 |
Why?
|
Nurses | 1 | 2021 | 40 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2021 | 133 | 0.050 |
Why?
|
Area Under Curve | 1 | 2020 | 34 | 0.050 |
Why?
|
Government Programs | 1 | 2020 | 11 | 0.050 |
Why?
|
Absorptiometry, Photon | 1 | 2020 | 52 | 0.050 |
Why?
|
Health Priorities | 1 | 2020 | 28 | 0.040 |
Why?
|
Kinetics | 2 | 2015 | 12 | 0.040 |
Why?
|
Recurrence | 1 | 2020 | 187 | 0.040 |
Why?
|
Health Resources | 1 | 2018 | 38 | 0.040 |
Why?
|
Scotland | 1 | 2018 | 3 | 0.040 |
Why?
|
Physical Abuse | 1 | 2018 | 2 | 0.040 |
Why?
|
Respiration | 1 | 2018 | 8 | 0.040 |
Why?
|
Electrons | 1 | 2018 | 1 | 0.040 |
Why?
|
Stereoisomerism | 1 | 2018 | 2 | 0.040 |
Why?
|
Hydrogen | 1 | 2018 | 3 | 0.040 |
Why?
|
Memory | 1 | 2018 | 12 | 0.040 |
Why?
|
Tandem Mass Spectrometry | 1 | 2018 | 6 | 0.040 |
Why?
|
Amino Acid Sequence | 1 | 2018 | 9 | 0.040 |
Why?
|
Amino Acids | 1 | 2018 | 3 | 0.040 |
Why?
|
Emotions | 1 | 2018 | 35 | 0.040 |
Why?
|
Bortezomib | 1 | 2017 | 1 | 0.040 |
Why?
|
Melphalan | 1 | 2017 | 2 | 0.040 |
Why?
|
Medical Record Linkage | 1 | 2018 | 44 | 0.040 |
Why?
|
Prednisone | 1 | 2017 | 5 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2017 | 23 | 0.040 |
Why?
|
Disease-Free Survival | 1 | 2017 | 57 | 0.040 |
Why?
|
Infection | 1 | 2017 | 17 | 0.040 |
Why?
|
Obesity | 1 | 2024 | 855 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 131 | 0.040 |
Why?
|
Cognition | 1 | 2018 | 82 | 0.040 |
Why?
|
Time | 1 | 2016 | 20 | 0.030 |
Why?
|
Waiting Lists | 1 | 2016 | 12 | 0.030 |
Why?
|
Comprehension | 1 | 2016 | 16 | 0.030 |
Why?
|
Muscarinic Antagonists | 1 | 2016 | 5 | 0.030 |
Why?
|
Administration, Inhalation | 1 | 2016 | 37 | 0.030 |
Why?
|
Nuclear Family | 1 | 2015 | 7 | 0.030 |
Why?
|
Medical Assistance | 1 | 2015 | 10 | 0.030 |
Why?
|
Lung Diseases | 1 | 2015 | 43 | 0.030 |
Why?
|
Research | 1 | 2016 | 73 | 0.030 |
Why?
|
Syndrome | 1 | 2015 | 29 | 0.030 |
Why?
|
Photolysis | 1 | 2015 | 1 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2015 | 6 | 0.030 |
Why?
|
Minority Groups | 1 | 2016 | 105 | 0.030 |
Why?
|
Clinical Competence | 1 | 2015 | 108 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2014 | 160 | 0.030 |
Why?
|
Odds Ratio | 1 | 2016 | 701 | 0.030 |
Why?
|
Atrial Natriuretic Factor | 2 | 2005 | 2 | 0.030 |
Why?
|
Protein Transport | 2 | 2005 | 4 | 0.030 |
Why?
|
Cell Line | 2 | 2005 | 9 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2014 | 365 | 0.030 |
Why?
|
Americas | 1 | 2013 | 2 | 0.030 |
Why?
|
Practice Patterns, Physicians' | 1 | 2016 | 350 | 0.030 |
Why?
|
Northwestern United States | 1 | 2013 | 58 | 0.030 |
Why?
|
Medication Adherence | 1 | 2016 | 267 | 0.030 |
Why?
|
Ethnic Groups | 1 | 2016 | 501 | 0.030 |
Why?
|
Educational Status | 1 | 2013 | 205 | 0.030 |
Why?
|
Loneliness | 1 | 2012 | 6 | 0.030 |
Why?
|
Transfection | 2 | 2002 | 6 | 0.030 |
Why?
|
Psychological Tests | 1 | 2010 | 11 | 0.020 |
Why?
|
Muscle Strength | 1 | 2009 | 14 | 0.020 |
Why?
|
Least-Squares Analysis | 1 | 2008 | 16 | 0.020 |
Why?
|
Utilization Review | 1 | 2008 | 56 | 0.020 |
Why?
|
Health Services Needs and Demand | 1 | 2009 | 109 | 0.020 |
Why?
|
Neoplasms | 1 | 2013 | 457 | 0.020 |
Why?
|
Pacific Islands | 1 | 2005 | 5 | 0.020 |
Why?
|
Immunity, Herd | 1 | 2005 | 5 | 0.020 |
Why?
|
Transportation | 1 | 2005 | 13 | 0.020 |
Why?
|
Measles Vaccine | 1 | 2005 | 21 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2005 | 46 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2005 | 47 | 0.020 |
Why?
|
Sickness Impact Profile | 1 | 2005 | 28 | 0.020 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2005 | 1 | 0.020 |
Why?
|
Schools | 1 | 2005 | 89 | 0.020 |
Why?
|
Mutation | 1 | 2005 | 132 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2005 | 872 | 0.010 |
Why?
|
Cyclic GMP | 1 | 2002 | 1 | 0.010 |
Why?
|
Platelet-Derived Growth Factor | 1 | 2002 | 1 | 0.010 |
Why?
|
Angiotensin II | 1 | 2002 | 2 | 0.010 |
Why?
|
Phosphorylation | 1 | 2002 | 4 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2002 | 3 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2002 | 11 | 0.010 |
Why?
|
Autopsy | 1 | 2002 | 15 | 0.010 |
Why?
|
Signal Transduction | 1 | 2002 | 30 | 0.010 |
Why?
|
Binding, Competitive | 1 | 2001 | 1 | 0.010 |
Why?
|
Plasmids | 1 | 2001 | 1 | 0.010 |
Why?
|
Ligands | 1 | 2001 | 6 | 0.010 |
Why?
|
Protein Binding | 1 | 2001 | 9 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2001 | 14 | 0.010 |
Why?
|
Rats | 1 | 2001 | 29 | 0.010 |
Why?
|
Temperature | 1 | 2001 | 18 | 0.010 |
Why?
|
Models, Biological | 1 | 2001 | 32 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2001 | 131 | 0.010 |
Why?
|
Animals | 1 | 2001 | 261 | 0.010 |
Why?
|